Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology Co's ROE % for the quarter that ended in Dec. 2025 was 7.42%. Medlive Technology Co's PB Ratio for the quarter that ended in Dec. 2025 was 1.34.
Medlive Technology Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 5.54%.
Medlive Technology Co ROE % Adjusted to Book Value Related Terms
Medlive Technology Co ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Medlive Technology Co's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co ROE % Adjusted to Book Value Chart
HKSE:02192 vs VEEV, BTSG, HQY: ROE % Adjusted to Book Value Comparison
For the Health Information Services subindustry, Medlive Technology Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medlive Technology Co ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medlive Technology Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Medlive Technology Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 5.54% mean?
Medlive Technology Co (HKSE:02192) has a ROE % Adjusted to Book Value of 5.54% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Medlive Technology Co and its competitors.
Is Medlive Technology Co's ROE % Adjusted to Book Value too high?
Medlive Technology Co's current ROE % Adjusted to Book Value is 5.54%. Overall, Medlive Technology Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's ROE % Adjusted to Book Value compare to VEEV and BTSG?
Medlive Technology Co's ROE % Adjusted to Book Value of 5.54% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Medlive Technology Co and its competitors. Medlive Technology Co's current ROE % Adjusted to Book Value is 5.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Medlive Technology Co (HKSE:02192) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.95, compared to a current price of HK$7.87 — trading 47.4% below its estimated fair value. The current ROE % Adjusted to Book Value is 5.54%. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Medlive Technology Co (HKSE:02192), the current ROE % Adjusted to Book Value is 5.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (HKSE:02192) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of HK$7.87 is trading 47.4% below its estimated GF Value™ of HK$14.95.
GuruFocus considers Medlive Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02192:
ROE % Adjusted to Book Value: 5.54%
GF Value™: HK$14.95 vs. price of HK$7.87 (47.4% below fair value)
No single metric tells the full story. See the HKSE:02192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for HKSE:02192
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02192 has been successfully added to your 
